U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H13F2N.ClH
Molecular Weight 233.685
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MOFEGILINE HYDROCHLORIDE

SMILES

Cl.NC\C(CCC1=CC=C(F)C=C1)=C\F

InChI

InChIKey=QUCNNQHLIHGBIA-HCUGZAAXSA-N
InChI=1S/C11H13F2N.ClH/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9;/h3-7H,1-2,8,14H2;1H/b10-7+;

HIDE SMILES / InChI

Molecular Formula C11H13F2N
Molecular Weight 197.2244
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Mofegiline (MDL 72,974A or (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, hydrochloride), is a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B) both in vitro and in vivo. In addition, mofegiline inhibits semicarbazide-sensitive amine oxidase activity from human serum and saphenous vein. In phase II studies, MDL 72,974A is proving to be a useful adjunct to conventional therapy of Parkinson's disease. It seems mofegiline development was discontinued.

Originator

Curator's Comment: Palfreyman et al., 1988 ( Merrell Dow Research Institute, Cincinnati, Ohio.)

Approval Year

Targets

Targets

Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27202 pg/mL
48 mg single, oral
dose: 48 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14018 pg/mL
24 mg 1 times / day steady-state, oral
dose: 24 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105170 pg × h/mL
48 mg single, oral
dose: 48 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
54359 pg × h/mL
24 mg 1 times / day steady-state, oral
dose: 24 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.02 h
48 mg single, oral
dose: 48 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.79 h
24 mg 1 times / day steady-state, oral
dose: 24 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MOFEGILINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
48 mg single, oral
Highest studied dose
Dose: 48 mg
Route: oral
Route: single
Dose: 48 mg
Sources: Page: p.349
healthy, ADULT
n = 3
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 3
Sources: Page: p.349
24 mg 1 times / day steady-state, oral
Studied dose
Dose: 24 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 24 mg, 1 times / day
Sources: Page: p.349
healthy, ADULT
n = 3
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 3
Sources: Page: p.349
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
1988
Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine.
2004 Sep
Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B.
2008 Dec 25
Patents

Sample Use Guides

In human volunteers, potent inhibition of platelet MAO-B activity was observed at submilligram doses (ED50 = 90 micrograms) following a single oral dose. Upon multiple oral doses of 100 micrograms, as much as 80% of MAO-B could be inhibited. In phase II studies, Mofegiline (MDL 72,974A) is proving to be a useful adjunct to conventional therapy. Patients (250) with Parkinson's disease, treated once daily with either 1 or 4 mg, together with L-Dopa and a decarboxylase inhibitor (MadoparR or SinemetR), saw significant improvements in symptoms compared with those on standard therapy without the inhibitor.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:37:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:37:36 GMT 2023
Record UNII
08331R10RY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOFEGILINE HYDROCHLORIDE
MI   USAN  
USAN  
Official Name English
(E)-2-(FLUOROMETHYLENE)-4-(P-FLUOROPHENYL)BUTYLAMINE HYDROCHLORIDE
Common Name English
MDL 72,974A
Code English
MOFEGILINE HYDROCHLORIDE [MI]
Common Name English
MOFEGILINE HCL
Common Name English
MDL-72974A
Code English
MOFEGILINE HYDROCHLORIDE [USAN]
Common Name English
BENZENEBUTANAMINE, 4-FLUORO-.BETA.-(FLUOROMETHYLENE)-, HYDROCHLORIDE, (E)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C667
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
Code System Code Type Description
PUBCHEM
6446650
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
MERCK INDEX
m831
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY Merck Index
CAS
120635-25-8
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
FDA UNII
08331R10RY
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
USAN
DD-55
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL489079
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
NCI_THESAURUS
C80965
Created by admin on Fri Dec 15 15:37:36 GMT 2023 , Edited by admin on Fri Dec 15 15:37:36 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY